Summary
⚈ Compass Therapeutics and Blade Air Mobility are highlighted for strong growth prospects.
⚈ Analysts predict significant upside potential for both stocks in the next year.
With the first month of Q2 nearly over, May presents a fresh opportunity to enter the stock market despite ongoing trade tensions and resulting volatility.
As things stand, the market looks set to close April positively, buoyed by hopes of easing trade tensions between China and the U.S.
In this environment, penny stocks could offer an attractive entry point, especially if optimism around trade tariffs resolutions continues to build. Known for their affordability and growth potential, penny stocks remain a popular investment choice.
In this context, Finbold has selected Compass Therapeutics (NASDAQ: CMPX) and Blade Air Mobility (NASDAQ: BLDE) as promising picks for May.
Compass Therapeutics (NASDAQ: CMPX)
Compass Therapeutics has achieved an impressive stock performance in 2025, primarily driven by the company’s strong 2024 results and the momentum behind its clinical advancements.
Currently trading at $1.94, CMPX has climbed more than 38% year-to-date.
Compass appears to have more growth potential, as it is progressing with CTX-10726, a PD-1 x VEGF-A bispecific antibody, with an IND submission planned by the end of 2025.
Recent preclinical data presented at the American Association for Cancer Research Annual Meeting highlighted the potential of CTX-009 and CTX-471 to treat tumors resistant to conventional immuno-oncology therapies.
With Phase 2 biomarker trials slated to begin in mid-2025, Compass is gaining attention as a penny stock with exciting upside potential.
Meanwhile, six Wall Street analysts tracked by TipRanks expect CMPX to soar by 527% over the next year, assigning the stock a consensus “Buy” rating and an average price target of $12.
Blade Air Mobility (NASDAQ: BLDE)
Blade Air Mobility, a technology-enabled air transport platform, delivers helicopter and fixed-wing services across the Northeast U.S., Southern Europe, and Western Canada. Its focus is on medical and passenger transportation.
In 2025, the company’s medical business, which specializes in organ transplant logistics, is expected to post double-digit growth, powered by new legislation and technological advances in perfusion systems.
Additionally, Blade’s financial position has strengthened, with the entity achieving positive cash flow, expanding profit margins, and maintaining a debt-free balance sheet of $136 million in cash. This provides ample room for fleet growth and potential share buybacks.
Although BLDE has rallied more than 4% over the past week to $2.71, it remains down over 36% year to date.
Still, Wall Street remains optimistic, with three analysts on TipRanks rating the stock a ‘Buy.’ They forecast a 117% upside over the next 12 months, with an average price target of $5.83.
Featured image via Shutterstock
